Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin

Clinical Therapeutics

Volumn 29, Issue 1, 2007, Pages 172-176

  Schindler, Christoph ^a   Thorns, Marcus ^b   Matschke, Klaus ^b   Tugtekin, Sems Malte ^b   Kirch, Wilhelm ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

heart transplant; pravastatin; rhabdomyolysis

Indexed keywords

ALLOPURINOL; ANTILIPEMIC AGENT; ATORVASTATIN; AZATHIOPRINE; CARVEDILOL; CERIVASTATIN; CLOPIDOGREL; CYCLOSPORIN; DILTIAZEM; ESOMEPRAZOLE; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOSUPPRESSIVE AGENT; INSULIN; MEVINOLIN; PRAVASTATIN; PREDNISOLONE; RAMIPRIL; SIMVASTATIN;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DRUG MONITORING; DRUG WITHDRAWAL; DYSPNEA; GERIATRIC PATIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MALE; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; RATING SCALE; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; AGED; CREATINE KINASE; DYSPNEA; HEART TRANSPLANTATION; HUMANS; HYDROPHOBICITY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MUSCLE CELLS; PRAVASTATIN; PROBABILITY; RHABDOMYOLYSIS; TIME FACTORS;

EID: 33947133282     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.01.017     Document Type: Article

References (22)

1. Siirtola A., Ketomaki A., Miettinen T.A., et al. Cholesterol absorption and synthesis in pediatric kidney, liver, and heart transplant recipients. Transplantation 81 (2006) 327-334
2. Seipelt I.M., Crawford S.E., Rodgers S., et al. Hypercholesterolemia is common after pediatric heart transplantation: Initial experience with pravastatin. J Heart Lung Transplant 23 (2004) 317-322
3. Kapadia S.R., Nissen S.E., Ziada K.M., et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: A serial intravascular ultrasound study. J Am Coll Cardiol 38 (2001) 206-213
4. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 (1995) 621-627
5. Jones T. The effect of HMG-CoA reductase inhibitors on chronic allograft rejection. Expert Opin Emerg Drugs 6 (2001) 95-109
6. Mehra M.R., and Raval N.Y. Metaanalysis of statins and survival in de novo cardiac transplantation. Transplant Proc 36 (2004) 1539-1541
7. Stojanovic I., Vrtovec B., Radovancevic B., et al. Survival, graft atherosclerosis, and rejection incidence in heart transplant recipients treated with statins: 5-Year followup. J Heart Lung Transplant 24 (2005) 1235-1238
8. Kobashigawa J.A., Moriguchi J.D., Laks H., et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 24 (2005) 1736-1740
9. (Suppl). Bruckert E., Hayem G., Dejager S., and Yau C. Risk of muscular symptoms with high dosage statin therapy in 7924 hyperlipidemic patients in French clinical practice. Abstract. J Am Coll Cardiol 45 (2005) 412A
10. [published correction appears in Pharmacol Ther. 2000;86:199]. Corsini A., Bellosta S., Baetta R., et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84 (1999) 413-428
11. Biggs M.J., Bonser R.S., and Cram R. Localized rhabdomyolysis after exertion in a cardiac transplant recipient on statin therapy. J Heart Lung Transplant 25 (2006) 356-357
12. Unnikrishnan D., and Satish B. Exertioninduced rhabdomyolysis in a patient on statin therapy. Nephrol Dial Transplant 20 (2005) 244
13. Jardine A., and Holdaas H. Fluvastatin in combination with cyclosporin in renal transplant recipients: A review of clinical and safety experience. J Clin Pharm Ther 24 (1999) 397-408
14. Keogh A., Macdonald P., Kaan A., et al. Efficacy and safety of pravastatin vs simvastatin after cardiac trans plantation. J Heart Lung Transplant 19 (2000) 529-537
15. Pasternak R.C., Smith Jr. S.C., BaireyMerz C.N., et al., American College of Cardiology. American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/ NHLBI Clinical Advisory on the use and safety of statins. Stroke 33 (2002) 2337-2341
16. Staffa J.A., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 (2002) 539-540
17. Omar M.A., and Wilson J.P. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 36 (2002) 288-295
18. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690
19. Flint O.P., Masters B.A., Gregg R.E., and Durham S.K. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 145 (1997) 91-98
20. De Pinieux G., Chariot P., Ammi-Said M., et al. Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/ pyruvate ratio. Br J Clin Pharmacol 42 (1996) 333-337
21. Phillips P.S., Haas R.H., Bannykh S., et al. Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137 (2002) 581-585
22. Motomura N., Saito S., and Foegh M.L. HMG-CoA reductase inhibitors in organ transplantation. J Nephrol 10 (1997) 68-76